Advanced

Vasculitis in rheumatoid arthritis.

Turesson, Carl LU and Matteson, Eric L (2009) In Current Opinion in Rheumatology 21(1). p.35-40
Abstract
PURPOSE OF REVIEW: To examine the occurrence and pathophysiology of vasculitis in rheumatoid arthritis (RA), describe the epidemiology and clinical features, and provide a therapeutic perspective. RECENT FINDINGS: With improved control of RA over the past two decades, the risk of severe outcomes such as vasculitis may be decreasing. Rheumatoid vasculitis continues to be associated with longstanding, erosive, seropositive disease, and it has recently been shown to be more frequent among patients with antibodies to cyclic citrullinated peptides. Apart from circulating immune complexes, expansion of cytotoxic CD28null T cells and circulating proinflammatory cytokines also play a role in the pathogenesis. The role of agents directed against... (More)
PURPOSE OF REVIEW: To examine the occurrence and pathophysiology of vasculitis in rheumatoid arthritis (RA), describe the epidemiology and clinical features, and provide a therapeutic perspective. RECENT FINDINGS: With improved control of RA over the past two decades, the risk of severe outcomes such as vasculitis may be decreasing. Rheumatoid vasculitis continues to be associated with longstanding, erosive, seropositive disease, and it has recently been shown to be more frequent among patients with antibodies to cyclic citrullinated peptides. Apart from circulating immune complexes, expansion of cytotoxic CD28null T cells and circulating proinflammatory cytokines also play a role in the pathogenesis. The role of agents directed against the tumor necrosis factor (TNF) in the occurrence and management of rheumatoid vasculitis remains unclear, as rheumatoid vasculitis may be both associated with and treated with anti-TNF agents, once it has appeared. SUMMARY: Vasculitis in RA is generally associated with longstanding disease, has an important impact on a patient's well being, and markedly influences patient life expectancy. Advances in therapies for RA will likely continue to reduce the incidence of vasculitis, and improved management of cardiovascular comorbidity in patients with RA will be of particular benefit to those who suffer from vasculitis and other extraarticular manifestations. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Current Opinion in Rheumatology
volume
21
issue
1
pages
35 - 40
publisher
Lippincott Williams & Wilkins
external identifiers
  • wos:000262336200007
  • pmid:19077716
  • scopus:58149229396
ISSN
1531-6963
DOI
10.1097/BOR.0b013e32831c5303
language
English
LU publication?
yes
id
d976d9a0-a6e3-40be-913f-bed5d30b7603 (old id 1276212)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19077716?dopt=Abstract
date added to LUP
2009-01-09 12:20:33
date last changed
2017-11-05 04:42:55
@article{d976d9a0-a6e3-40be-913f-bed5d30b7603,
  abstract     = {PURPOSE OF REVIEW: To examine the occurrence and pathophysiology of vasculitis in rheumatoid arthritis (RA), describe the epidemiology and clinical features, and provide a therapeutic perspective. RECENT FINDINGS: With improved control of RA over the past two decades, the risk of severe outcomes such as vasculitis may be decreasing. Rheumatoid vasculitis continues to be associated with longstanding, erosive, seropositive disease, and it has recently been shown to be more frequent among patients with antibodies to cyclic citrullinated peptides. Apart from circulating immune complexes, expansion of cytotoxic CD28null T cells and circulating proinflammatory cytokines also play a role in the pathogenesis. The role of agents directed against the tumor necrosis factor (TNF) in the occurrence and management of rheumatoid vasculitis remains unclear, as rheumatoid vasculitis may be both associated with and treated with anti-TNF agents, once it has appeared. SUMMARY: Vasculitis in RA is generally associated with longstanding disease, has an important impact on a patient's well being, and markedly influences patient life expectancy. Advances in therapies for RA will likely continue to reduce the incidence of vasculitis, and improved management of cardiovascular comorbidity in patients with RA will be of particular benefit to those who suffer from vasculitis and other extraarticular manifestations.},
  author       = {Turesson, Carl and Matteson, Eric L},
  issn         = {1531-6963},
  language     = {eng},
  number       = {1},
  pages        = {35--40},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Current Opinion in Rheumatology},
  title        = {Vasculitis in rheumatoid arthritis.},
  url          = {http://dx.doi.org/10.1097/BOR.0b013e32831c5303},
  volume       = {21},
  year         = {2009},
}